Outcome of the first exercise period for ChromoGenics warrants of series 2020/2022:1
The first exercise period of two has now been completed regarding the warrants of series 2020/2022: 1 ("ChromoGenics TO 2020/2022" or "Warrant") that ChromoGenics AB ("ChromoGenics" or "the Company") issued in connection with a rights issue of units at the end of 2020 ("Rights Issue"). ChromoGenics will receive approximately SEK 0.5 million before issue costs through the exercise of the Warrants.At the end of 2020, ChromoGenics carried out an issue of units, consisting of shares and warrants, with preferential rights for existing shareholders. The terms of the Rights Issue meant that five (